Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ruilope, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ruilope, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Proven benefits of angiotensin receptor blockers in the progression of renal disease

L. Ruilope*

Hospital 12 de Octubre, Servicio de Nefrologia, Madrid, Spain

* Correspondence: L. Ruilope, Hospital 12 de Octubre, Servicio de Nefrologia, Madrid, Spain.

Abstract

Angiotensin-receptor blockers are recommended by the American Diabetes Association as first-line treatments for patients with diabetic nephropathy. This recommendation is based on impressive results from a series of clinical trials which reported in 2001 and 2002. The trials showed renal benefits beyond and possibly unrelated to blood-pressure reductions. More such data on protection from cardiovascular outcomes and possible mortality benefits are expected to be provided by the VALUE (Valsartan Long-Term Use Evaluation) trial, which has a high proportion of patients with diabetes and/or proteinuria. This trial is due to report in 2004.

Key Words: Diabetic nephropathy • INDT • MARVAL • RENAAL • renal protection • urinary albumin excretion rates • VALUE


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HypertensionHome page
A. M. Sharma
Is There a Rationale for Angiotensin Blockade in the Management of Obesity Hypertension?
Hypertension, July 1, 2004; 44(1): 12 - 19.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.